FKBPL Activators
FKBPL Activators are a diverse array of chemical compounds that leverage the intricate web of signaling pathways and protein interactions to enhance the functional activity of FKBPL. Tamoxifen and Raloxifene, both selective estrogen receptor modulators, exert their influence on FKBPL by modulating estrogen receptor signaling, leading to potential stabilization and activation of FKBPL's role in cellular stress response mechanisms and anti-angiogenesis. Similarly, Fulvestrant's mechanism of estrogen receptor degradationmay inadvertently promote FKBPL activity by shifting the hormonal signaling dynamics, potentially increasing FKBPL's availability and functional engagement in cellular homeostasis. Compounds like 17-AAG, Geldanamycin, Celastrol, Novobiocin, BIIB021, and Radicicol, all function as Hsp90 inhibitors, which can indirectly stabilize FKBPL and elevate its activity, particularly in protein folding and degradation pathways, as well as in exerting anti-cancer effects. This stabilization is paramount as it possibly enhances FKBPL's chaperone activity, thereby maintaining proteostasis and contributing to its anti-angiogenic properties.
Withaferin A, by inhibiting proteasomal degradation, could preserve FKBPL levels and thus potentiate its regulatory role in proteostasis and angiogenesis inhibition. Sirolimus intersects with the mTOR signaling pathway, an axis that FKBPL may regulate, leading to an indirect amplification of its function in protein synthesis and cell proliferation control. Lastly, Phenethyl Isothiocyanate, by modulating the Keap1-Nrf2 oxidative stress pathway, could bolster FKBPL's involvement in redox balance, enhancing its capacity to manage oxidative stress. These activators collectively contribute to the heightened functional state of FKBPL, underscoring its significance in various biological processes without necessitating increased expression or direct activation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
As a selective estrogen receptor modulator, Tamoxifen can influence estrogen signaling pathways. FKBPL is known to interact with estrogen receptors, and tamoxifen-binding may promote FKBPL stabilization and enhance its activity in cellular stress response mechanisms. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG is an Hsp90 inhibitor that can lead to the stabilization of Hsp90 client proteins, including FKBPL, potentially increasing its functional activity in protein folding and degradation pathways. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Similar to 17-AAG, Geldanamycin binds to Hsp90, potentially enhancing the stability and activity of FKBPL as an Hsp90 co-chaperone, which may indirectly increase the functional activity of FKBPL in stress response pathways. | ||||||
Raloxifene | 84449-90-1 | sc-476458 | 1 g | $802.00 | 3 | |
Raloxifene, another selective estrogen receptor modulator, may increase FKBPL's activity by modulating estrogen receptor-related pathways, possibly leading to an enhanced role of FKBPL in anti-angiogenic processes. | ||||||
ICI 182,780 | 129453-61-8 | sc-203435 sc-203435A | 1 mg 10 mg | $83.00 $187.00 | 34 | |
Fulvestrant, an estrogen receptor degrader, might indirectly enhance FKBPL activity by altering the balance of estrogen receptor signaling, which could increase the bioavailability and functional role of FKBPL in cellular homeostasis. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A is known to inhibit the proteasomal degradation of proteins. This could stabilize FKBPL, enhancing its functional activity in regulating proteostasis and anti-angiogenic functions. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $158.00 | 6 | |
Celastrol, a known Hsp90 inhibitor, may enhance FKBPL activity by stabilizing its structure and function within the protein folding pathways, potentially increasing its anti-angiogenic activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Sirolimus, an mTOR inhibitor, could indirectly increase FKBPL activity by modulating the mTOR signaling pathway, which is involved in protein synthesis and cell proliferation, processes where FKBPL might play a regulatory role. | ||||||
Novobiocin | 303-81-1 | sc-362034 sc-362034A | 5 mg 25 mg | $128.00 $380.00 | ||
Novobiocin is another Hsp90 inhibitor that could stabilize FKBPL, enhancing its activity in chaperoning proteins and possibly promoting its anti-cancer properties. | ||||||
BIIB 021 | 848695-25-0 | sc-364434 sc-364434A | 5 mg 25 mg | $128.00 $650.00 | ||
BIIB021 is an oral Hsp90 inhibitor that potentially increases FKBPL stability and activity, enhancing its role in protein homeostasis. | ||||||